Technical Analysis for APTO - Aptose Biosciences, Inc.

Grade Last Price % Change Price Change
grade C 2.21 -1.78% -0.04
APTO closed down 1.78 percent on Friday, January 18, 2019, on 54 percent of normal volume. It was able to find support at its 50 day moving average.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Down
See historical APTO trend table...

Date Alert Name Type % Chg
Jan 18 50 DMA Support Bullish 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 17 Wide Bands Range Expansion -1.78%
Jan 16 Pocket Pivot Bullish Swing Setup -3.49%
Jan 16 Upper Bollinger Band Touch Strength -3.49%
Jan 15 Crossed Above 50 DMA Bullish -1.34%
Jan 14 50 DMA Resistance Bearish 5.24%
Jan 14 20 DMA Support Bullish 5.24%
Jan 14 NR7 Range Contraction 5.24%
Jan 14 NR7-2 Range Contraction 5.24%

Older signals for APTO ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Aptose Biosciences Inc., a biopharmaceutical company, is engaged in the discovery, research, and development of novel anticancer therapies in Canada. The company's pipeline of cancer drug candidates includes small molecule therapies and immunotherapy. Its lead program, LOR-253, an anticancer agent, which has completed Phase I clinical trail for the treatment of solid tumors, as well as undergoing Phase II clinical trials for the treatment of relapsed/refractory hematologic malignancies. The company's discovery stage products include LOR-500, a MELK Inhibitor for Oncology, as well as small molecule programs. The company is also developing RNA-targeted therapies, including LOR-2040, an antisense ribonucleotide reductase (R2) synthesis inhibitor, which is in Phase III clinical trial for the treatment of acute myeloid leukemia; and Virulizin, a novel immunotherapy agent that has completed three Phase I/II clinical studies in solid tumors and pancreatic cancers, as well as completed a randomized placebo-controlled Phase III clinical trial for the treatment of pancreatic cancer in combination with gemcitabine. In addition, its preclinical stage products comprise LOR-220, a novel small molecule for drug-resistant bacterial infections; and IL-17E1, an immuno-modulator for oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Toronto, Canada.
Is APTO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 4.55
52 Week Low 1.78
Average Volume 185,896
200-Day Moving Average 2.8587
50-Day Moving Average 2.1647
20-Day Moving Average 2.117
10-Day Moving Average 2.239
Average True Range 0.1756
ADX 21.75
+DI 25.1232
-DI 14.2334
Chandelier Exit (Long, 3 ATRs ) 2.0032
Chandelier Exit (Short, 3 ATRs ) 2.3068
Upper Bollinger Band 2.4392
Lower Bollinger Band 1.7948
Percent B (%b) 0.64
BandWidth 30.439301
MACD Line 0.0264
MACD Signal Line 0.0118
MACD Histogram 0.0145
Fundamentals Value
Market Cap 53.11 Million
Num Shares 24 Million
EPS -0.78
Price-to-Earnings (P/E) Ratio -2.83
Price-to-Sales 0.00
Price-to-Book 2.86
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.36
Resistance 3 (R3) 2.36 2.31 2.34
Resistance 2 (R2) 2.31 2.27 2.31 2.33
Resistance 1 (R1) 2.26 2.25 2.24 2.26 2.32
Pivot Point 2.21 2.21 2.20 2.21 2.21
Support 1 (S1) 2.16 2.17 2.14 2.16 2.10
Support 2 (S2) 2.11 2.15 2.11 2.09
Support 3 (S3) 2.06 2.11 2.09
Support 4 (S4) 2.06